Literature DB >> 26590713

Breast Tumor Heterogeneity: Source of Fitness, Hurdle for Therapy.

Shany Koren1, Mohamed Bentires-Alj2.   

Abstract

Tumor heterogeneity impinges on prognosis, response to therapy, and metastasis. As such, heterogeneity is one of the most important and clinically relevant areas of cancer research. Breast cancer displays frequent intra- and inter-tumor heterogeneity as the result of genetic and non-genetic alterations that often enhance the vigor of cancer cells. In-depth characterization and understanding of the origin of this phenotypic and molecular diversity is paramount to improving diagnosis, the definition of prognostic and predictive biomarkers, and the design of therapeutic strategies. Here, we summarize current knowledge about sources of breast cancer heterogeneity, its consequences, and possible counter-measures. We discuss especially the impact on tumor heterogeneity of the differentiation state of the cell-of-origin, cancer cell plasticity, the microenvironment, and genetic evolution. Factors that enhance cancer cell vigor are clearly detrimental for patients.
Copyright © 2015 Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Year:  2015        PMID: 26590713     DOI: 10.1016/j.molcel.2015.10.031

Source DB:  PubMed          Journal:  Mol Cell        ISSN: 1097-2765            Impact factor:   17.970


  97 in total

1.  α-Parvin promotes breast cancer progression and metastasis through interaction with G3BP2 and regulation of TWIST1 signaling.

Authors:  Ying Sun; Yanyan Ding; Chen Guo; Chengmin Liu; Ping Ma; Shuang Ma; Zhe Wang; Jie Liu; Tao Qian; Luyao Ma; Yi Deng; Chuanyue Wu
Journal:  Oncogene       Date:  2019-02-25       Impact factor: 9.867

2.  Imaging-guided revival of nanomedicine?

Authors:  Max L Senders; Zahi A Fayad; Thomas Reiner; Willem Jm Mulder; Carlos Pérez-Medina
Journal:  Nanomedicine (Lond)       Date:  2016-11-23       Impact factor: 5.307

3.  BRCA1 ensures genome integrity by eliminating estrogen-induced pathological topoisomerase II-DNA complexes.

Authors:  Hiroyuki Sasanuma; Masataka Tsuda; Suguru Morimoto; Liton Kumar Saha; Md Maminur Rahman; Yusuke Kiyooka; Haruna Fujiike; Andrew D Cherniack; Junji Itou; Elsa Callen Moreu; Masakazu Toi; Shinichiro Nakada; Hisashi Tanaka; Ken Tsutsui; Shintaro Yamada; Andre Nussenzweig; Shunichi Takeda
Journal:  Proc Natl Acad Sci U S A       Date:  2018-10-23       Impact factor: 11.205

4.  Design and synthesis of cenocladamide analogues and their evaluation against breast cancer cell lines.

Authors:  Carla C F Santos; Luciana S Paradela; Luiz F T Novaes; Sandra M G Dias; Julio C Pastre
Journal:  Medchemcomm       Date:  2016-11-25       Impact factor: 3.597

5.  The implementation of a commercially available multi-gene profile test for breast cancer characterization in a department of pathology: what have we learned from the first 100 cases?

Authors:  Cristina Pelliccia; Emanuele Caselli; Martina Mandarano; Rachele Del Sordo; Guido Bellezza; Angelo Sidoni
Journal:  Virchows Arch       Date:  2021-01-06       Impact factor: 4.064

6.  Revealing tumor heterogeneity of breast cancer by utilizing the linkage between somatic and germline mutations.

Authors:  Meng Zou; Rui Jin; Kin Fai Au
Journal:  Brief Bioinform       Date:  2019-11-27       Impact factor: 11.622

7.  LRG1 mRNA expression in breast cancer associates with PIK3CA genotype and with aromatase inhibitor therapy outcome.

Authors:  Diana E Ramirez-Ardila; Kirsten Ruigrok-Ritstier; Jean C Helmijr; Maxime P Look; Steven van Laere; Luc Dirix; Els M J J Berns; Maurice P H M Jansen
Journal:  Mol Oncol       Date:  2016-07-25       Impact factor: 6.603

Review 8.  Clonal cooperativity in heterogenous cancers.

Authors:  Hengbo Zhou; Deepika Neelakantan; Heide L Ford
Journal:  Semin Cell Dev Biol       Date:  2016-08-28       Impact factor: 7.727

9.  Kallikrein-related peptidase 6 (KLK6) expression differentiates tumor subtypes and predicts clinical outcome in breast cancer patients.

Authors:  Christoforos Haritos; Kleita Michaelidou; Konstantinos Mavridis; Ioannis Missitzis; Alexandros Ardavanis; John Griniatsos; Andreas Scorilas
Journal:  Clin Exp Med       Date:  2018-02-12       Impact factor: 3.984

10.  Interleukin-8 Dedifferentiates Primary Human Luminal Cells to Multipotent Stem Cells.

Authors:  Huda H Al-Khalaf; Hazem Ghebeh; Salma M Wakil; Falah Al-Mohanna; Abdelilah Aboussekhra
Journal:  Mol Cell Biol       Date:  2020-04-13       Impact factor: 4.272

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.